- within Transport topic(s)
Last week, Takeda announced that it has entered into a worldwide license and collaboration agreement (outside of Greater China) with Innovent Biologics for the development, manufacture, and commercialization of two late-stage oncology medicines, IBI363 and IBI343. According to Takeda, IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein, is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343, an antibody-drug conjugate that targets the Claudin 18.2 protein, is being evaluated in gastric and pancreatic cancers.
Upon closing, Innovent Biologics will receive a $1.2 billion upfront payment, which includes an equity investment of $100 million. Innovent Biologics will also be eligible for potential milestones and royalty payments. Under the terms of the agreement, Takeda will lead co-commercialization efforts of IBI363 in the U.S. and will have the exclusive right to commercialize IBI363 outside of the U.S. and Greater China; Takeda will have global manufacturing rights to supply IBI363 outside of Greater China, and co-exclusive rights with Innovent Biologics for commercial supply in the U.S. Takeda will develop, manufacture, and commercialize IBI343 worldwide, outside of Greater China.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
